整合生物学期刊网

应用天然产物 ›› 2024, Vol. 14 ›› Issue (3): 20-20.DOI: 10.1007/s13659-024-00441-3

• REVIEWS • 上一篇    下一篇

Current advances on the therapeutic potential of scutellarin: an updated review

Yifei Xie1, Guotong Sun3, Yue Tao2, Wen Zhang1, Shiying Yang2, Li Zhang2, Yang Lu2, Guanhua Du1   

  1. 1 Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing 100050, China;
    2 Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
    3 Pharmaceutical College of Henan University, Kaifeng 475004, China
  • 收稿日期:2023-11-20 发布日期:2024-06-14
  • 通讯作者: Li Zhang,E-mail:zhangl@imm.ac.cn;Yang Lu,E-mail:luy@imm.ac.cn;Guanhua Du,E-mail:dugh@imm.ac.cn
  • 基金资助:
    This funding was supported by National Science Foundation of China (22278443); the Key R&D Program of Shan Dong Province (2021ZDSYS26); Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2022-I2M-1-015, 2022-I2M-1-005);Chinese Pharmacopoeia Commission Drug Standard Promoting Fund (2023Y11); Jiangsu Provincial Agricultural Science and Technology Independent Innovation Fund (2202GH15); Special Fund for Scientific Innovation Strategy-Construction of High-level Academy of Agriculture Science (2022D04016); National Natural Science Foundation of China (882141204).

Current advances on the therapeutic potential of scutellarin: an updated review

Yifei Xie1, Guotong Sun3, Yue Tao2, Wen Zhang1, Shiying Yang2, Li Zhang2, Yang Lu2, Guanhua Du1   

  1. 1 Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing 100050, China;
    2 Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
    3 Pharmaceutical College of Henan University, Kaifeng 475004, China
  • Received:2023-11-20 Published:2024-06-14
  • Contact: Li Zhang,E-mail:zhangl@imm.ac.cn;Yang Lu,E-mail:luy@imm.ac.cn;Guanhua Du,E-mail:dugh@imm.ac.cn
  • Supported by:
    This funding was supported by National Science Foundation of China (22278443); the Key R&D Program of Shan Dong Province (2021ZDSYS26); Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2022-I2M-1-015, 2022-I2M-1-005);Chinese Pharmacopoeia Commission Drug Standard Promoting Fund (2023Y11); Jiangsu Provincial Agricultural Science and Technology Independent Innovation Fund (2202GH15); Special Fund for Scientific Innovation Strategy-Construction of High-level Academy of Agriculture Science (2022D04016); National Natural Science Foundation of China (882141204).

摘要: Scutellarin is widely distributed in Scutellaria baicalensis, family Labiatae, and Calendula officinalis, family Asteraceae, and belongs to flavonoids. Scutellarin has a wide range of pharmacological activities, it is widely used in the treatment of cerebral infarction, angina pectoris, cerebral thrombosis, coronary heart disease, and other diseases. It is a natural product with great research and development prospects. In recent years, with in-depth research, researchers have found that wild scutellarin also has good therapeutic effects in anti-tumor, anti-inflammatory, anti-oxidation, anti-virus, treatment of metabolic diseases, and protection of kidney. The cancer treatment involves glioma, breast cancer, lung cancer, renal cancer, colon cancer, and so on. In this paper, the sources, pharmacological effects, in vivo and in vitro models of scutellarin were summarized in recent years, and the current research status and future direction of scutellarin were analyzed.

关键词: Scutellarin, Pharmacological action, Experimental study, Model, Mechanism

Abstract: Scutellarin is widely distributed in Scutellaria baicalensis, family Labiatae, and Calendula officinalis, family Asteraceae, and belongs to flavonoids. Scutellarin has a wide range of pharmacological activities, it is widely used in the treatment of cerebral infarction, angina pectoris, cerebral thrombosis, coronary heart disease, and other diseases. It is a natural product with great research and development prospects. In recent years, with in-depth research, researchers have found that wild scutellarin also has good therapeutic effects in anti-tumor, anti-inflammatory, anti-oxidation, anti-virus, treatment of metabolic diseases, and protection of kidney. The cancer treatment involves glioma, breast cancer, lung cancer, renal cancer, colon cancer, and so on. In this paper, the sources, pharmacological effects, in vivo and in vitro models of scutellarin were summarized in recent years, and the current research status and future direction of scutellarin were analyzed.

Key words: Scutellarin, Pharmacological action, Experimental study, Model, Mechanism